When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis.
Prince
F H M
FH
Twilt
M
M
Simon
S C M
SC
van Rossum
M A J
MA
Armbrust
W
W
Hoppenreijs
E P A H
EP
Kamphuis
S
S
van Santen-Hoeufft
M
M
Koopman-Keemink
Y
Y
Wulffraat
N M
NM
ten Cate
R
R
van Suijlekom-Smit
L W A
LW
D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001171:Arthritis, Juvenile / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D008297:Male; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D016896:Treatment Outcome; D028761:Withholding Treatment
D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept